Targeting B Cells and Plasma Cells in Glomerular Disease

Area of Science:

• Immunology
• Nephrology

Background:

• Autoantibodies produced by B cells and plasma cells are key drivers of glomerular diseases.
• Current non-targeted immunosuppression has limitations, including side effects and treatment resistance.

Purpose of the Study:

• To review the biology of antibody-secreting cells in glomerular diseases.
• To focus on and evaluate therapeutics specifically targeting B cells and plasma cells.

Main Methods:

• Review of B-cell depletion strategies (e.g., anti-CD20, BAFF/APRIL inhibition, BCR inhibition).
• Review of plasma cell-directed therapies (e.g., proteasome inhibitors, anti-CD38).
• Discussion of novel therapeutic approaches (e.g., CAR-T therapy, bispecific T-cell engagers).

Main Results:

• B-cell and plasma cell targeted therapies offer specific treatment avenues for glomerular diseases.
• Understanding mechanisms of therapeutic resistance is crucial for optimizing treatment outcomes.

Conclusions:

• Targeted therapies against B cells and plasma cells represent a promising strategy for managing glomerular diseases.
• Further research into novel agents and resistance mechanisms is needed to improve patient care.